alectinib + erlotinib

A combination of alectinib and erlotinib would represent the concurrent use of two oral small molecule tyrosine kinase inhibitors, each targeting different oncogenic pathways in cancer. **Alectinib** is a selective, second-generation inhibitor of anaplastic lymphoma kinase (**ALK**), used primarily in ALK-positive non-small cell lung cancer (NSCLC)[2]. **Erlotinib** is an inhibitor of the epidermal growth factor receptor (**EGFR**) tyrosine kinase, indicated for advanced NSCLC with specific EGFR mutations, and for pancreatic cancer[5]. Both drugs inhibit their respective kinases to prevent downstream signaling that drives tumor cell proliferation and survival. No clinical evidence was identified for the use of alectinib and erlotinib as a combination therapy; rather, the most common investigational combinations involve alectinib with angiogenesis inhibitors (e.g., bevacizumab) and erlotinib with angiogenesis inhibitors or as monotherapy in distinct genetic subtypes of NSCLC[1][3].

Other names

alectinib hydrochlorideerlotinib hydrochloride